Stockscreener 앱 받기
9.18
2.96%
-0.28
Artelo Biosciences Inc 주식(ARTL)의 최신 뉴스
Artelo Biosciences Ends Securities Purchase Agreement - TipRanks
Artelo Biosciences terminates securities purchase agreement - MarketScreener
Artelo Biosciences Inc. Rebounds From Oversold Zone — Now What2025 Big Picture & High Return Stock Watch Alerts - beatles.ru
Artelo Biosciences: Boral Capital Maintains Buy Rating, PT Raised to $18. - AInvest
Artelo Biosciences Q2 2025 Earnings Miss Market Expectations; Short-Term Optimism Tempered by Broader Sector Trends - AInvest
Is Artelo Biosciences Inc. being accumulated by smart money2025 Analyst Calls & Comprehensive Market Scan Insights - thegnnews.com
Artelo Biosciences Sees Bullish Trend with KDJ Golden Cross and Bullish Marubozu - AInvest
Artelo Biosciences Q2 2025 Earnings: Negative Earnings, Mixed Market Reactions - AInvest
Artelo Biosciences Inc. Building a Base Near SupportWeekly Profit Report & Fast Gain Swing Trade Alerts - sundaytimes.kr
Artelo Biosciences Reports Increased Losses Amid Strategic Investments - TipRanks
Artelo Biosciences reports Q2 EPS ($5.61) vs. ($4.52) last year - TipRanks
Artelo Biosciences Q2 Earnings: $5.61 EPS, FABP5 Inhibitor Pipeline Advances - AInvest
Artelo Biosciences Provides Business Update and Reports Second Q - GuruFocus
ARTELO BIOSCIENCES, INC. SEC 10-Q Report - TradingView
Artelo Biosciences Provides Business Update and Reports Second Quarter 2025 Financial Results - MarketScreener
Artelo Biosciences Nears Major Clinical Readouts as Cash Position Strengthens to $13M - Stock Titan
Is It Too Early to Call Recovery in Artelo Biosciences Inc.July 2025 Fed Impact & AI Powered Market Entry Ideas - 선데이타임즈
Artelo Biosciences Receives Patent Protection Extension in Europe - mg Magazine
How to interpret RSI for Artelo Biosciences Inc. stockFree Portfolio Diversification Stock Ideas - Newser
Chart based exit strategy for Artelo Biosciences Inc.Free Optimized Watchlist With Daily Adjustments - Newser
Will Artelo Biosciences Inc. rebound enough to break evenBuy and Hold Return Summary with Charts - Newser
Artelo Biosciences Secures European Patent for ART27.13 Commercial Formulation, Extending Protection Through 2041 - AInvest
Risk vs reward if holding onto Artelo Biosciences Inc.ROI Focused Setup With Drawdown Analysis - Newser
Artelo Biosciences Surges 19.4% on Landmark Patent Approval for Cancer Anorexia Drug ART27.13 - AInvest
Artelo Biosciences secures European patent protection for cancer drug By Investing.com - Investing.com Nigeria
Artelo Biosciences secures European patent protection for cancer drug - Investing.com
Artelo Biosciences Receives Notice of Allowance from - GlobeNewswire
Artelo Biosciences Receives Notice of Allowance from European Patent Office for the Patent Claims for the Intended Commercial Formulation of ART27.13 - MarketScreener
European Patent Win Secures 20-Year Protection for Revolutionary Cancer Anorexia Treatment in Phase 2 Trials - Stock Titan
Technical signs of recovery in Artelo Biosciences Inc.Free Value Investing Picks With Stability - Newser
What institutional flow reveals about Artelo Biosciences Inc.Breakout Watcher with Entry and Exit Alerts - Newser
Using Bollinger Bands to evaluate Artelo Biosciences Inc.Intraday Signal Forecast for Fast Traders - Newser
Multi factor analysis applied to Artelo Biosciences Inc.Swing Trade Watchlist with Entry Zones - Newser
Does Artelo Biosciences Inc. qualify in momentum factor screeningTrading Volume Anomaly Summary and Insight - Newser
Solana News Today: Solana Climbs 4.05% as Artelo Biosciences Invests $9.475M in Treasury - AInvest
Combining price and volume data for Artelo Biosciences Inc.Forecast Model for Intraday Buy Signals - Newser
Artelo Biosciences Partners with ABK Labs for Strategic Growth - The Globe and Mail
Artelo Biosciences (ARTL) down more than 70% since Jul 11 - AInvest
Artelo Biosciences Inc. Moves Into Bullish Territory Based on MACDEntry Alert With Low Drawdown Strategy Noted - beatles.ru
Will a bounce in Artelo Biosciences Inc. offer an exitTrade Ideas Based on Fundamental Metrics - Newser
Artelo Biosciences Closes $9.475 Million Private Placement to Adopt Solana as Core Reserve Asset - AInvest
Artelo Biosciences (ARTL) down more than 50% since Jul 10 - AInvest
Artelo Biosciences Sees 15min Chart Trigger KDJ Golden Cross, Bullish Marubozu - AInvest
Analyst Maintains Buy Rating on ARTL with Target Price of $18 | - GuruFocus
Artelo Biosciences: Boral Capital maintains Buy, PT raised to $18 from $15. - AInvest
Biocardia Stock Plunges 12.76% Amid Market Volatility - AInvest
Artelo Biosciences stock soars after announcing $9.5M private placement for Solana-based treasury - Investing.com Canada
Artelo Biosciences (ARTL): D. Boral Capital Adjusts Price Target, Maintains Buy Rating | ARTL Stock News - GuruFocus
Artelo Biosciences stock rating reaffirmed at Buy by D. Boral Capital - Investing.com India
Solana News Today: Artelo Biosciences Allocates $9.475M to Build Solana Digital Asset Reserve Strategy - AInvest
Artelo Biosciences announces private placement to initiate Solana treasury - TipRanks
Artelo Biosciences shares surge after unveiling $9.5M private placement tied to Solana-based treasury plan - MSN
Solana News Today: Artelo Biosciences Adopts Solana as Treasury Asset After $9.475M Raise - AInvest
Artelo Biosciences Soars 13.73% on Clinical Trial Success, Blockchain Strategy - AInvest
Artelo Biosciences Initiates SOL Treasury Strategy with PIPE Financing, Partnering with CUBE and Bartosz Lipiński - Quiver Quantitative
Artelo Biosciences Announces $9.475 Million At-the-Market Private Placement to Initiate Solana Treasury Strategy, Becoming First Publicly-Traded Pharmaceutical Company to Adopt SOL as a Core Reserve Asset - The Manila Times
Artelo Biosciences raises $9.5M, adopts Solana as treasury asset By Investing.com - Investing.com Nigeria
Artelo Biosciences raises $9.5M, adopts Solana as treasury asset - Investing.com India
Artelo Biosciences raises $9.5M in PIPE, expands SOL treasury management strategy. - AInvest
Artelo Biosciences Announces $9.475 Million At-the-Market - GlobeNewswire
0.51%
1.14%
자본화:
|
볼륨(24시간):